It’s always good to be at the forefront of something special.
Back in 2009 The London Nail Laser Clinic became the European pioneer of the PinPointe FootLaser – a dramatic breakthrough in the treatment of onychomycosis (nail fungus).
Three years on, it’s been confirmed this month that already more than 100,000 procedures have been performed worldwide using PinPointe. That’s a remarkable statistic, and even more so when you consider that it outstrips many of the other treatment options put together. But then again, maybe we shouldn’t be so surprised.
The PinPointe FootLaser was, after all, the first light-based device to be formally approved by the medical regulators the USA, where it was developed by NuvoLase. And, even as we approach 2013, it remains one of an elite few devices on the market today with documented, clinically proven efficacy.
Small wonder that Steven Duddy, boss of NuvoLase in California, describes the global progression beyond 100,000 treatments as an “exciting and important milestone”.
Requiring no anaesthetic, the PinPointe FootLaser uses a laser infra red light to pass through into the nail and nail bed. This light is absorbed by the fungal cells, specifically causing them to vaporise. Not only is it an effective alternative to potentially risky oral medications, there are no side effects. Nor is there any recovery period or effect on activity after treatment.
As one leading foot surgeon in America put it: “This breakthrough technology has changed the way we approach patients suffering from unsightly nail fungus and has changed the lives of many.”
The London Nail Laser Clinic continues to embrace and enhance the technology, with impressive results. Nearly all patients receiving treatment show some degree of improvement at six months – and more than three quarters of these show significant healthy nail growth.